InsiderSignal.AI

InsiderSignal.ai

ANNX - Annexon, Inc.

Insider Sale by Lew Jennifer (EVP, CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Lew Jennifer, serving as EVP, CFO at Annexon, Inc. (ANNX), sold 5,565 shares at $5.42 per share, for a total transaction value of $30,162.00. Following this transaction, Lew Jennifer now holds 170,700 shares of ANNX.

This sale represents a 3.00% decrease in Lew Jennifer's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 2 days after the trade was made.

Annexon, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Lew Jennifer

Lew Jennifer

EVP, CFO

Jennifer Lew is the Executive Vice President and Chief Financial Officer (EVP & CFO) of Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company focused on developing therapies for complement-mediated disorders, a role she has held since June 2019.[[1]](https://fintool.com/app/research/companies/ANNX/people/jennifer-lew)[[4]](https://boundlessbio.com/who-we-are/jennifer-lew/)[[6]](https://annexonbio.com/about/) In this position, she has led key financial initiatives, including the company's initial public offering in 2020, and oversees finance, accounting, investor relations, and strategic planning amid the firm's pre-commercial stage with ongoing net losses.[[1]](https://fintool.com/app/research/companies/ANNX/people/jennifer-lew)[[4]](https://boundlessbio.com/who-we-are/jennifer-lew/) Lew brings over two decades of finance leadership in biotechnology, previously serving as CFO of Aduro Biotech (January 2018–May 2019), where she managed an IPO and merger activities; Vice President of Finance and Principal Accounting Officer at Dynavax Technologies (2004–2013); Director of Finance and Assistant Controller at QRS Corporation (2000–2004); and Audit Manager at Ernst & Young (1994–1999).[[1]](https://fintool.com/app/research/companies/ANNX/people/jennifer-lew)[[2]](https://fintool.com/app/research/companies/BOLD/people/jennifer-lew)[[3]](https://theorg.com/org/annexon-biosciences/org-chart/jennifer-lew)[[4]](https://boundlessbio.com/who-we-are/jennifer-lew/) She holds a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive).[[1]](https://fintool.com/app/research/companies/ANNX/people/jennifer-lew)[[3]](https://theorg.com/org/annexon-biosciences/org-chart/jennifer-lew) Additionally, she serves as an independent director and Audit Committee Chair at Boundless Bio, Inc. (NASDAQ: BOLD) since January 2022.[[2]](https://fintool.com/app/research/companies/BOLD/people/jennifer-lew)[[4]](https://boundlessbio.com/who-we-are/jennifer-lew/) As a corporate insider, she has engaged in recent trading related to equity awards at Annexon.[[5]](https://www.gurufocus.com/insider/29504/jennifer-lew)

View full insider profile →

Trade Price

$5.42

Quantity

5,565

Total Value

$30,162.00

Shares Owned

170,700

Trade Date

Monday, March 2, 2026

3 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Annexon, Inc.

Company Overview

No company information available
View news mentioning ANNX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4496973

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime